Vancomycin Side Effects: What Studies Report

What the published literature covers

Vancomycin is a glycopeptide antibiotic that has been used clinically for decades, primarily against Gram-positive organisms including methicillin-resistant Staphylococcus aureus (MRSA). A narrative review of its therapeutic and adverse effects summarised both its clinical applications and the adverse effects most often attributed to it, including nephrotoxicity, ototoxicity and infusion-related reactions (PMID 25753888). Because vancomycin is an approved prescription medicine rather than an investigational material, the safety literature draws on randomised trials, large observational cohorts, therapeutic-monitoring studies and individual case reports.

Evidence tier: Established. The adverse-effect categories described below appear repeatedly across peer-reviewed reviews, controlled trials and meta-analyses rather than in isolated reports alone, although the frequency and severity attributed to each category vary considerably between study populations and settings.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medication, adverse effect or laboratory result. Nothing here describes how vancomycin should be administered, monitored or combined with other medicines.

Kidney Effects: What Studies Report

Acute kidney injury is the most extensively studied adverse outcome. A 2017 clinical pharmacology review of vancomycin nephrotoxicity examined the reported incidence of renal injury across published cohorts, the proposed mechanisms of proximal tubular and oxidative injury, and the risk factors most consistently identified, including greater vancomycin exposure, longer duration of therapy, critical illness and concurrent administration of other nephrotoxic agents (PMID 28474732). The same review discussed why exposure-guided monitoring approaches have been proposed as a way of characterising renal risk, and noted the difficulty of separating drug effect from underlying illness in observational data (PMID 28474732).

Comparative trial data point in a similar direction. In a randomised, controlled study of linezolid versus vancomycin for MRSA nosocomial pneumonia, researchers reported that nephrotoxicity occurred more frequently among patients who received vancomycin than among those who received linezolid (PMID 22247123). A 2015 review likewise identified nephrotoxicity as a principal dose- and exposure-related concern in clinical use of the drug (PMID 25753888).

Hearing and Vestibular Effects: What Studies Report

Ototoxicity has historically been linked to vancomycin, and the 2015 review of therapeutic and adverse effects listed hearing-related toxicity among the adverse effects described in the clinical literature, while noting that modern preparations and monitoring practices differ from those in earlier reports (PMID 25753888). Published reviews generally treat ototoxicity as less frequently documented than renal injury, and as difficult to attribute when patients receive several potentially ototoxic agents at once (PMID 25753888).

Infusion-Related and Skin Reactions: What Studies Report

Reactions associated with intravenous administration — historically described as "red man" or vancomycin flushing reactions, with flushing, rash, pruritus and hypotension — were summarised in the review of vancomycin's adverse effects as among the more commonly encountered problems in practice (PMID 25753888).

Delayed immune-mediated skin reactions have also been documented. A 2020 case report described vancomycin-induced linear IgA bullous dermatosis, a blistering eruption in which the authors reported that the lesions were temporally associated with vancomycin exposure and improved after the drug was withdrawn (PMID 33456152). As a single case, that report describes a recognised pattern rather than an estimated frequency (PMID 33456152).

Blood Count Changes: What Studies Report

Haematological adverse effects appear mainly in case-level literature. A 2024 report described two cases of vancomycin-induced neutropenia, in which the authors reported that neutrophil counts fell during vancomycin therapy and recovered after the drug was stopped (PMID 38392944). The authors of that report discussed neutropenia as an uncommon but recognised complication of prolonged therapy (PMID 38392944). Broader reviews of the drug's adverse-effect profile also list haematological abnormalities among reported effects (PMID 25753888).

Electrolyte and Metabolic Findings: What Studies Report

A 2020 proof-of-concept case report described vancomycin-associated hypokalemia, with the authors reporting that potassium levels tracked with vancomycin exposure in the patient described and proposing a mechanistic explanation for the observation (PMID 32682800). Findings of this kind are hypothesis-generating: the study documented a single patient and did not establish how often such an electrolyte disturbance occurs in treated populations (PMID 32682800).

Serum Concentrations and Outcomes: What Studies Report

Several studies have examined whether measured vancomycin concentrations relate to adverse outcomes rather than to adverse drug effects alone. In patients with peritoneal dialysis-associated peritonitis, researchers reported that serum vancomycin levels were associated with short-term adverse outcomes in that cohort (PMID 35021905). The 2017 nephrotoxicity review discussed the same general theme from a renal perspective, considering how exposure measures have been used to describe the relationship between vancomycin concentrations and kidney injury (PMID 28474732).

A 2025 case report described the effects of intravenous vancomycin administration on peritonitis in a patient receiving peritoneal dialysis, illustrating how route of administration and dialysis status are discussed together in this literature (PMID 41341563).

Comparative Safety Against Other MRSA Agents: What Studies Report

Because vancomycin has long been a comparator drug in MRSA trials, several syntheses report its safety alongside alternatives. A 2023 systematic review and meta-analysis assessed the effectiveness and safety of linezolid versus vancomycin, teicoplanin or daptomycin in MRSA bacteraemia, and the authors reported pooled comparisons for both efficacy and adverse-event outcomes across the included studies (PMID 37107059). A 2024 systematic review and network meta-analysis of antibiotics for MRSA infections likewise evaluated efficacy and safety across multiple agents, placing vancomycin within a wider comparative framework (PMID 39335039).

Randomised evidence contributes to the same picture: in the MRSA nosocomial pneumonia trial, researchers reported differing adverse-event patterns between the vancomycin and linezolid arms, with renal adverse events more frequent in the vancomycin group (PMID 22247123).

Procedural and Local Administration Settings: What Studies Report

Vancomycin safety has also been examined outside systemic infection treatment. A 2024 report evaluated the efficacy and safety of large-scale use of vancomycin added to the infusion bottle during vitreoretinal procedures, and the authors reported outcomes from that surgical series (PMID 39132119). Studies in procedural settings are not interchangeable with systemic-therapy safety data, because exposure, duration and patient populations differ substantially (PMID 39132119).

Laboratory and Formulation Work

Some published work addresses vancomycin chemistry rather than patient outcomes. A 2022 study described silica-coated magnetic nanoparticles prepared for vancomycin conjugation, and the authors reported the synthesis and characterisation of those conjugates in a laboratory setting (PMID 36061717). Laboratory formulation studies of this kind describe material properties and do not report human adverse-effect data (PMID 36061717).

What This Literature Does and Does Not Establish

• Case reports show patterns, not rates. The neutropenia, dermatosis and hypokalemia reports documented individual patients and did not estimate population frequency (PMID 38392944, PMID 33456152, PMID 32682800).
• Attribution is difficult in observational data. The nephrotoxicity review discussed confounding from critical illness and concomitant nephrotoxic drugs when renal injury is attributed to vancomycin (PMID 28474732).
• Pooled comparisons depend on the trials available. The 2023 and 2024 syntheses reported comparative safety within the limits of the included study designs and populations (PMID 37107059, PMID 39335039).
• Setting matters. Findings from dialysis-associated peritonitis and intraocular surgical prophylaxis do not generalise to other clinical contexts (PMID 35021905, PMID 39132119).

Regulatory and Naming Notes

Vancomycin is an approved prescription antibiotic in many jurisdictions and is supplied as intravenous and oral products under generic and brand names. Prescribing, monitoring and product labelling are the domain of licensed clinicians, pharmacists and national regulators, and approved product labelling is the authoritative source for safety information. Any brand name for a vancomycin-containing product is a trademark of its owner, and PeptideU is not affiliated with or endorsed by any manufacturer, brand owner or trademark holder mentioned or implied on this page. PeptideU sells nothing and describes published findings for educational reading only.

A separate PeptideU learning course covers vancomycin pharmacology, mechanism and clinical context in more depth; this page is limited to summarising what published studies reported about adverse effects and comparative safety.

References

• The Nephrotoxicity of Vancomycin (Clinical Pharmacology and Therapeutics, 2017)
• The use of vancomycin with its therapeutic and adverse effects: a review (European Review for Medical and Pharmacological Sciences, 2015)
• Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study (Clinical Infectious Diseases, 2012)
• Effectiveness and Safety of Linezolid Versus Vancomycin, Teicoplanin, or Daptomycin against Methicillin-Resistant Staphylococcus aureus Bacteremia: A Systematic Review and Meta-Analysis (Antibiotics, 2023)
• Efficacy and Safety of Antibiotics in the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections: A Systematic Review and Network Meta-Analysis (Antibiotics, 2024)
• Two Cases of Vancomycin-Induced Neutropenia (Pharmacy, 2024)
• Vancomycin-induced linear IgA bullous dermatosis (Proceedings, Baylor University Medical Center, 2020)
• Vancomycin-induced hypokalemia: A proof-of-concept case report (Clinica Chimica Acta, 2020)
• Serum vancomycin levels predict the short-term adverse outcomes of peritoneal dialysis-associated peritonitis (Peritoneal Dialysis International, 2023)
• Effects of Intravenous Administration of Vancomycin on Peritonitis in a Patient on Peritoneal Dialysis (Clinical Case Reports, 2025)
• Efficacy and safety of large-scale use of vancomycin injection in infusion bottle during vitreoretinal procedures (Oman Journal of Ophthalmology, 2024)
• Silica-Coated Magnetic Nanoparticles for Vancomycin Conjugation (ACS Omega, 2022)